TAMPA, FL—UTEK Corporation (AMEX:UTK), an open innovation company focused on technology transfer, and EntreMed Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced they have signed a Technology Acquisition Alliance.

“The technology acquisition alliance with UTEK provides EntreMed with global access to intellectual property that can supplement our existing pipeline. We will continue to build our oncology franchise through a combination of internal development and selective technology and product acquisitions,” said James S. Burns, president and CEO of EntreMed Inc.

EntreMed’s goal is to develop and commercialize new compounds based on the company’s expertise in angiogenesis, cell-cycle regulation and inflammation – processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis.

Through its Technology Acquisition Alliances, UTEK assists companies in enhancing their new product pipeline with the acquisition of proprietary intellectual capital from universities and laboratory research centers.

UTEK’s services enable companies to acquire externally developed technologies from universities and research laboratories worldwide. In addition, UTEK provides services to help companies create value from their intellectual property.

On the Web: www.entremed.com
www.utekcorp.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2007, TechJournal South. All rights reserved.